Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668261 | 0.76 | ESR1 (0.41) | — | |
| SCHEMBL11508291 | 0.74 | IDO1 (0.34) | NAAA | |
| SCHEMBL7789783 | 0.74 | KCNH2 (0.43) | KCNH2HRH3LTA4HSCARB1SMN1; SMN2 | |
| SCHEMBL132013 | 0.72 | KCNH2 (0.49) | KCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL3607804 | 0.71 | ALDH1A1 (0.47) | KCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL5464687 | 0.71 | NPC1 (0.43) | KCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL27494571 | 0.70 | KCNH2 (0.36) | KCNH2HRH3LTA4HSCARB1SMN1; SMN2 | |
| SCHEMBL105809 | 0.69 | NPC1 (0.41) | KCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL20410837 | 0.69 | KCNH2 (0.44) | KCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL8855985 | 0.68 | KCNH2 (0.38) | KCNH2HRH3LTA4HSCARB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |